Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer

Cancer Letters

Volumn 314, Issue 1, 2012, Pages 119-125

  Liu, Qing Hua ^a   Zhang, Jing ^a   Zhao, Chen Yan ^a   Yu, Dang Hui ^a   Bu, Hai Ji ^a   Chen, Ying ^a   Ni, Can Yong ^a   Zhu, Ming Hua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Gemcitabine; Intrinsic chemoresistance; Surviving cells

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS;

EID: 82355175286     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.018     Document Type: Article

References (34)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA. Cancer J. Clin. 2010, 60:277-300.
2. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
3. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
4. Noordhuis P., Holwerda U., Van der Wilt C.L., Van Groeningen C.J., Smid K., Meijer S., Pinedo H.M., Peters G.J. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann. Oncol. 2004, 15:1025-1032.
5. Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol. 1996, 23:3-15.
6. Zhu C.P., Shi J., Chen Y.X., Xie W.F., Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother. Oncol. 2011, 99:108-113.
7. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
8. Song H.S., Do Y.R., Chang H.M., Ryu M.H., Lee K.H., Kim Y.H., Hong D.S., Cho J.Y., Lee K.E., Kim S.Y. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2008, 62:763-768.
9. Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., Wente M.N., Izbicki J.R., Friess H., Lerch M.M., Dervenis C., Olah A., Butturini G., Doi R., Lind P.A., Smith D., Valle J.W., Palmer D.H., Buckels J.A., Thompson J., McKay C.J., Rawcliffe C.L., Buchler M.W. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
10. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., Neuhaus H., Haag C., Clemens M., Heinrich B., Vehling-Kaiser U., Fuchs M., Fleckenstein D., Gesierich W., Uthgenannt D., Einsele H., Holstege A., Hinke A., Schalhorn A., Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006, 24:3946-3952.
11. Philip P.A., Benedetti J., Corless C.L., Wong R., O'Reilly E.M., Flynn P.J., Rowland K.M., Atkins J.N., Mirtsching B.C., Rivkin S.E., Khorana A.A., Goldman B., Fenoglio-Preiser C.M., Abbruzzese J.L., Blanke C.D. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 2010, 28:3605-3610.
12. Tortora G., Ciardiello F., Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat. Clin. Pract. Oncol. 2008, 5:521-530.
13. Byers L.A., Heymach J.V. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin. Lung Cancer 2007, 8(Suppl. 2):S79-S85.
14. Zatelli M.C., Luchin A., Piccin D., Tagliati F., Bottoni A., Vignali C., Bondanelli M., degli Uberti E.C. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 2005, 90:5754-5760.
15. Kang J.H., Song K.H., Jeong K.C., Kim S., Choi C., Lee C.H., Oh S.H. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC. Cancer 2011, 11:334.
16. Huanwen W., Zhiyong L., Xiaohua S., Xinyu R., Kai W., Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol. Cancer 2009, 8:125.
17. Melisi D., Xia Q., Paradiso G., Ling J., Moccia T., Carbone C., Budillon A., Abbruzzese J.L., Chiao P.J. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl. Cancer. Inst. 2011, 103:1190-1204.
18. Barouch-Bentov R., Sauer K. Mechanisms of drug resistance in kinases. Expert Opin. Investig. Drugs 2011, 20:153-208.
19. Lu X.Y., Cai Q., Ding K. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation. Curr. Med. Chem. 2011, 18:2146-2157.
20. Dhillon K.K., Swisher E.M., Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci. 2011, 102:663-669.
21. Pierotti M.A., Tamborini E., Negri T., Pricl S., Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat. Rev. Clin. Oncol. 2011, 8:161-170.
22. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117:2562-2569.
23. Kars M.D., Iseri O.D., Gündüz U., Ural A.U., Arpaci F., Molnár J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 2006, 26:4559-4568.
24. Wang X., Chen W., Zeng W., Bai L., Tesfaigzi Y., Belinsky S.A., Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol. Cancer Ther. 2008, 7:1156-1163.
25. M.Y. Merl, O. Abdelghany, J. Li, M.W. Saif, First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? in: Highlights from the " 2010 ASCO Annual Meeting" Chicago, IL, USA. June 4-8, 2010, JOP, vol. 11, pp. 317-320.
26. Trog D., Yeghiazaryan K., Fountoulakis M., Friedlein A., Moenkemann H., Haertel N., Schueller H., Breipohl W., Schild H., Leppert D., Golubnitschaja O. Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. Eur. J. Pharmacol. 2006, 542:8-15.
27. Alagkiozidis I., Facciabene A., Carpenito C., Benencia F., Jonak Z., Adams S., Carroll R.G., Gimotty P.A., Hammond R., Danet-Desnoyers G.A., June C.H., Powell D.J., Coukos G. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J. Transl. Med. 2009, 7:104.
28. Wu B.X., Zeidan Y.H., Hannun Y.A. Downregulation of neutral ceramidase by gemcitabine: implications for cell cycle regulation. Biochim. Biophys. Acta 2009, 1791:730-739.
29. Lee B.J., Chon K.M., Kim Y.S., An W.G., Roh H.J., Goh E.K., Wang S.G. Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. Chemotherapy 2005, 51:103-110.
30. Liu H.C., Chen G.G., Vlantis A.C., Leung B.C., Tong M.C., van Hasselt C.A. 5-Fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J. 2006, 12:482-493.
31. Huang Y., Waxman S. Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin. Cancer Res. 1998, 4:2503-2509.
32. Noma B., Sasaki T., Fujimoto Y., Serikawa M., Kobayashi K., Inoue M., Itsuki H., Kamigaki M., Minami T., Chayama K. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int. J. Oncol. 2008, 33:1187-1194.
33. Akada M., Crnogorac-Jurcevic T., Lattimore S., Mahon P., Lopes R., Sunamura M., Matsuno S., Lemoine N.R. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin. Cancer Res. 2005, 11:3094-3101.
34. Natoni F., Diolordi L., Santoni C., Gilardini Montani M.S. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim. Biophys. Acta 2005, 1745:318-329.